Klaria Pharma

Summary of the Interim Report

First quarter of 2024 The group in total

- Net sales 0.0 MSEK (6.5 MSEK)

- Other income 0.0 MSEK (0.1 MSEK)

- R&D expenses for the quarter amounted to 0.9 MSEK (8.6 MSEK)

- Profit after tax amounted to -11.9 MSEK (-5.4 MSEK)

- Earnings per share for the quarter amounted to -0.11 SEK (-0.06 SEK)

- Cash flow from operating activities amounted to -3.6 MSEK (-9.1 MSEK)

- Liquid assets on the balance sheet date amounted to 0.9 MSEK (13.1 MSEK)

- Equity as of March 31 amounted to 29.2 MSEK (70.7 MSEK)